Literature DB >> 12907242

Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.

Jennifer Sigmond1, Harold H J Backus, Dorine Wouters, Olaf H Temmink, Gerrit Jansen, Godefridus J Peters.   

Abstract

Pemetrexed (ALIMTA, MTA) is a novel thymidylate synthase (TS) inhibitor and has shown activity against colon cancer, mesothelioma and nonsmall-cell lung cancer. We induced resistance to Pemetrexed in the human colon cancer cell line WiDr by using a continuous exposure to stepwise increasing Pemetrexed concentrations (up to 20 microM) as well as a more clinically relevant schedule with intermittent exposure (up to 50 microM) for 4 hr every 7 days, resulting in WiDr variants WiDr-cPEM and WiDr-4PEM, respectively. However, using the same conditions, it was not possible to induce resistance in the WiDr/F cell line, a variant adapted to growth under low folate conditions. Mechanisms of resistance to Pemetrexed were determined at the level of TS, folylpolyglutamate synthetase (FPGS) and reduced folate carrier (RFC). WiDr-4PEM and WiDr-cPEM showed cross-resistance to the polyglutamatable TS inhibitor Raltitrexed (6- and 19-fold, respectively) and the nonpolyglutamatable TS-inhibitor Thymitaq (6- and 42-fold, respectively) but not to 5-fluorouracil. The ratios of TS mRNA:beta actin mRNA in WiDr-4PEM and WiDr-cPEM were 5-fold (P=0.01) and 18-fold (P=0.04) higher, respectively, compared to WiDr (ratio: 0.012). In addition, TS protein expression in the resistant WiDr variants was elevated 3-fold compared to WiDr, while the catalytic activity of TS with 1 microM dUMP increased from 30 pmol/hr/10(6) cells in WiDr cells to 2201 and 7663 pmol/hr/10(6) cells in WiDr-4PEM and WiDr-cPEM, respectively. The activity of FPGS was moderately decreased, but not significantly different in all WiDr variants. Finally, no evidence was found that decreased catalytic activity of RFC was responsible for the obtained Pemetrexed resistance. Altogether, these results indicate that resistance to Pemetrexed in the colon cancer cell line WiDr was solely due to upregulation of TS of which all related parameters (mRNA and protein expression and TS activity) were increased, rather than alterations in FPGS or RFC activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12907242     DOI: 10.1016/s0006-2952(03)00287-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  39 in total

Review 1.  Drug resistance in lung cancer.

Authors:  Manish Shanker; David Willcutts; Jack A Roth; Rajagopal Ramesh
Journal:  Lung Cancer (Auckl)       Date:  2010-05-08

2.  Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.

Authors:  T Masuda; H Imai; T Kuwako; Y Miura; R Yoshino; K Kaira; K Shimizu; N Sunaga; Y Tomizawa; S Ishihara; A Mogi; T Hisada; K Minato; A Takise; R Saito; M Yamada
Journal:  Clin Transl Oncol       Date:  2015-05-20       Impact factor: 3.405

Review 3.  Emerging treatment options in the management of non-small cell lung cancer.

Authors:  Pier Luigi Filosso; Alberto Sandri; Alberto Oliaro; Andrea Riccardo Filippi; Maria Carla Cassinis; Umberto Ricardi; Paolo Olivo Lausi; Sofia Asioli; Enrico Ruffini
Journal:  Lung Cancer (Auckl)       Date:  2011-06-08

4.  Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.

Authors:  Boyka Markova; Patricia S Hähnel; Stefan Kasper; Stephan Herbertz; Martin Schuler; Frank Breitenbuecher
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-28       Impact factor: 4.553

5.  Erlotinib with pemetrexed/cisplatin for patients with EGFR wild-type lung adenocarcinoma with brain metastases.

Authors:  Yalei Zhang; Haihong Yang; Xinyun Yang; Qiuhua Deng; Meilin Zhao; Xin Xu; Jianxing He
Journal:  Mol Clin Oncol       Date:  2014-02-11

6.  The similar survival benefits of stable disease and partial response to pemetrexed in previously treated non-small cell carcinoma patients.

Authors:  Hye-Ryoun Kim; Min Soo Kang; Im Il Na; Sung Hyeon Yang; Yoon Hee Choi; Hye Jin Kang; Cheol Hyeon Kim; Jae Cheol Lee
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-30       Impact factor: 4.553

7.  Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.

Authors:  Daniel E Schwed Lustgarten; Charuhas Deshpande; Charu Aggarwal; Liang-Chuan Wang; Vassiliki Saloura; Anil Vachani; Li-Ping Wang; Leslie Litzky; Michael Feldman; Jeanette Creaney; Anna K Nowak; Corey Langer; Simona Inghilleri; Giulia Stella; Steven M Albelda
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

Review 8.  Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer.

Authors:  Josephine Feliciano; Steven Feigenberg; Minesh Mehta
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

9.  Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.

Authors:  T Shimizu; Y Nakagawa; N Takahashi; S Hashimoto
Journal:  Clin Transl Oncol       Date:  2015-07-29       Impact factor: 3.405

10.  Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer.

Authors:  Serena Ricciardi; Silverio Tomao; Filippo de Marinis
Journal:  Ther Clin Risk Manag       Date:  2009-10-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.